Meeting
2015 ASCO Annual Meeting
Preclinical efficacy studies using HuMax-Axl-ADC, a novel antibody-drug conjugate targeting Axl-expressing solid cancers.
Authors
Esther CW Breij
Genmab, Utrecht, Netherlands
Esther CW Breij , Sandra Verploegen , Andreas Lingnau , Edward N van den Brink , Maarten Janmaat , Mischa Houtkamp , Wim Bleeker , David Satijn , Paul Parren
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Immunotherapy and Biologic Therapy
Citation
J Clin Oncol 33, 2015 (suppl; abstr 3066)
DOI
10.1200/jco.2015.33.15_suppl.3066
Abstract #
3066
Poster Bd #
392
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Antitumor activity of intraperitoneal (IP) paclitaxel to mucinous appendiceal adenocarcinoma in orthotopic patient-derived xenograft model.
First Author: Ichiaki Ito
Poster
2013 ASCO Annual Meeting
Use of an antibody-drug conjugate targeting tissue factor to induce complete tumor regression in xenograft models with heterogeneous target expression.
First Author: Esther CW Breij
Poster
2023 ASCO Annual Meeting
EGRET: A first-in-human study of the novel antibody-drug conjugate (ADC) AZD9592 as monotherapy or combined with other anticancer agents in patients (pts) with advanced solid tumors.
First Author: Charu Aggarwal
Poster
2020 ASCO Virtual Scientific Program
SKB264 ADC: A first-in-human study of SKB264 in patients with locally advanced unresectable/metastatic solid tumors who are refractory to available standard therapies.
First Author: Yongheng Liu